Experiences with
Bendeka8 public posts
Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor. (BRUIN CLL-321 Phase III trial results reported at ASH2024)
[/i]
[i]Median progression-free survival (PFS) reached 14 months with pirtobrutinib, an oral non-covalent BTK inhibitor, as compared with 8.7 months with investigator's choice of idelalisib (Zydelig) plus rituximab (Rituxan) or bendamustine (Bendeka, Treanda) plus rituximab (HR 0.54, 95% CI 0.39-0.75
Want to take advantage of all our features? Just log in!
or
Bendeka, a fast infusion form of bendamustine, gets 7 year exclusivity in U.S.
., for Bendeka (bendamustine hydrochloride injection, or bendamustine HCI), a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine hydrochloride. Bendeka is for the treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL).